ReviewAIMS public health2021
A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19.
Review in AIMS public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05502081 (Clinical Study to Evaluate the Possible Efficacy and Safety of Antibodies Combination), which is not on this map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Study to Evaluate the Possible Efficacy and Safety of Antibodies Combination (Casirivimab and Imdevimab) Versus Standard Antiviral Therapy (Remdesivir and Favipravir) as Antiviral Agent Against Corona Virus 2 Infection in Hospitalized COVID-19 Patients
Who cites it
32 citing papers in PubMed, 59 citations in OpenAlex.
- Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients.World journal of clinical cases · 2023Trial
- Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab.Journal of translational medicine · 2022Trial
- Central nervous system manifestations following vaccination against COVID-19.Brain, behavior, & immunity - health · 2024Review
- Discovering associations between radiological features and COVID-19 patients' deterioration.Health science reports · 2023Article
- A qualitative assessment of the adverse effects associated with COVID-19 vaccines: a study from Jordan.Journal of pharmaceutical policy and practice · 2023Article
- Clinical study to compare the efficacy and safety of casirivimab & imdevimab, remdesivir, and favipravir in hospitalized COVID-19 patients.Journal of clinical virology plus · 2023Article
- A cyclic behavioral modeling aspect to understand the effects of vaccination and treatment on epidemic transmission dynamics.Scientific reports · 2023Article
- A Systematic Review and Meta-Analysis Comparing the Diagnostic Accuracy Tests of COVID-19.Diagnostics (Basel, Switzerland) · 2023Review
- COVID-19 and hepatic injury: cellular and molecular mechanisms in diverse liver cells.World journal of gastroenterology · 2023Review
- Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients.Open medicine (Warsaw, Poland) · 2023Article
- Current clinical status of new COVID-19 vaccines and immunotherapy.Environmental science and pollution research international · 2022Review
- Recent advances in point of care testing for COVID-19 detection.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Support after COVID-19 study: a mixed-methods cross-sectional study to develop recommendations for practice.BMJ open · 2022Article
- COVID-19 Vaccines in Older Adults: Challenges in Vaccine Development and Policy Making.Clinics in geriatric medicine · 2022Review
- Laser-Induced Graphene-Functionalized Field-Effect Transistor-Based Biosensing: A Potent Candidate for COVID-19 Detection.IEEE transactions on nanobioscience · 2022Review
- A multi-targeted approach to identify potential flavonoids against three targets in the SARS-CoV-2 life cycle.Computers in biology and medicine · 2022Article
- Exploratory Study on Application of MALDI-TOF-MS to Detect SARS-CoV-2 Infection in Human Saliva.Journal of clinical medicine · 2022Article
- Factors Associated with Community Awareness on COVID-19 in a Developing Country: Implications for Optimal Risk Communication.Risk management and healthcare policy · 2022Article
- A Global Map of COVID-19 Vaccine Acceptance Rates per Country: An Updated Concise Narrative Review.Journal of multidisciplinary healthcare · 2022Review
- The Commonwealth Caribbean COVID-19: Regions Resilient Pathway During Pandemic.Frontiers in public health · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is caused by SARS-CoV-2, which originated in Wuhan, Hubei province, Central China, in December 2019 and since then has spread rapidly, resulting in a severe pandemic. The infected patient presents with varying non-specific symptoms requiring an accurate and rapid diagnostic tool to detect SARS-CoV-2. This is followed by effective patient isolation and early treatment initiation ranging from supportive therapy to specific drugs such as corticosteroids, antiviral agents, antibiotics, and the recently introduced convalescent plasma. The development of an efficient vaccine has been an on-going challenge by various nations and research companies. A literature search was conducted in early December 2020 in all the major databases such as Medline/PubMed, Web of Science, Scopus and Google Scholar search engines. The findings are discussed in three main thematic areas namely diagnostic approaches, therapeutic options, and potential vaccines in various phases of development. Therefore, an effective and economical vaccine remains the only retort to combat COVID-19 successfully to save millions of lives during this pandemic. However, there is a great scope for further research in discovering cost-effective and safer therapeutics, vaccines and strategies to ensure equitable access to COVID-19 prevention and treatment services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.